Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors
Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into an agreement to commercialize a proposed trastuzumab biosimilar.